中 EN

About Us

About Us

Let everyone have health
make life more energetic

Forging ahead in the tide of era, Brilliant Pharmaceuticals has always focused on pharmaceutical innovation and industrialization development.
Each milestone not only witnessed the company's original intention to protect the "beauty of life", but also wrote a journey of endeavor of a Chinese private pharmaceutical enterprise characterized by "Brilliant innovation" and "Brilliant efficiency".

2007-2012
Initial stage of the development

2007, acquired Sichuan Direction Pharmaceutical Co., Ltd.
2012, acquired Chengdu Brilliant Pharmaceutical Co., Ltd.
2012, Sichuan Purity Pharmaceutical Co., Ltd. was established

2013-2015
Independent R&D and manufacturing , Integration of API and FDF

2013, the company's first research institute Brilliant Pharmaceutical Research Institute was established
2014, the company's first FDF production base Shuangliu Production Base was completed
2015, the company's first API production base Ren'an Pharmaceuticals was completed

2016-2019
Business expansion to the whole country, establish small molecule innovative drug R&D institute

2017, acquired Hainan Brilliant Pharmaceutical Co., Ltd.
2018, acquired Chengdu Brilliant Dominate Pharmaceutical Co., Ltd. (small molecule innovative drug research institute)
2018, ScinnoHub Pharmaceuticals was established
2019, the shareholding reform of Brilliant Pharmaceuticals was completed

2020-2021
Enter the frontier field of biological medicine and strengthen industrial support

2020, Shanghai Hongcheng Biopharma was established
2020, Chengdu Brilliant Biopharma was established
2020, Hangzhou Brilliant Biopharma was established
2021, Chengdu Brilliant Inspiration Biotherapeutics Co., Ltd. was established
2021, acquired Sichuan Taipingyang Pharmaceutical Co., Ltd.

2022-2023
Radiopharmaceuticals and innovative Chinese patent medicine have been deployed in multiple locations to generate strong momentum for innovation

2022,The new headquarter park of Brilliant Pharmaceuticals was officially put into use
2022, Chengdu Brilliant Harpoon Biotechnology Co., Ltd. was established
2022, acquired Chengdu Syncor Pharmaceutical Co., Ltd.
2023, Sichuan Renning Pharmaceuticals High-end Chemical API project was commenced
2023, acquired Fuzhou Huaxialiangfang Biopharmaceutical Co., Ltd.
2023, Chengdu Haihe Pharmaceutical Technology Co., Ltd.

2024-Current
Advance the process of internationalization

2024, acquired Meyer Pharmaceuticals Ltd. in Hong Kong.
……